Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.09
-0.03 (-0.49%)
At close: Apr 28, 2026, 4:00 PM EDT
6.19
+0.10 (1.64%)
After-hours: Apr 28, 2026, 7:41 PM EDT
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Xeris Biopharma Holdings stock have an average target of 10.83, with a low estimate of 8.00 and a high estimate of 18. The average target predicts an increase of 77.83% from the current stock price of 6.09.
Analyst Consensus: Buy
* Price targets were last updated on Mar 2, 2026.
Analyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +64.20% | Mar 2, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +64.20% | Jan 9, 2026 |
| Barclays | Barclays | Buy Initiates $9 | Buy | Initiates | $9 | +47.78% | Dec 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $18 | Buy | Maintains | $18 | +195.57% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 | Strong Buy | Maintains | $10 | +64.20% | Nov 7, 2025 |
Financial Forecast
Revenue This Year
392.14M
from 291.85M
Increased by 34.37%
Revenue Next Year
481.79M
from 392.14M
Increased by 22.86%
EPS This Year
0.11
from 0.00
Increased by 3,444.08%
EPS Next Year
0.35
from 0.11
Increased by 207.69%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 409.2M | 528.2M | |||||
| Avg | 392.1M | 481.8M | |||||
| Low | 373.6M | 445.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 40.2% | 34.7% | |||||
| Avg | 34.4% | 22.9% | |||||
| Low | 28.0% | 13.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.21 | 0.48 | |
| Avg | 0.11 | 0.35 | |
| Low | 0.05 | 0.17 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 6,448.2% | 325.0% | |
| Avg | 3,444.1% | 207.7% | |
| Low | 1,427.9% | 46.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.